​

Nektar Therapeutics (NKTR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NKTR Stock Forecast

Nektar Therapeutics (NKTR) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $16.75, with a high of $24.00 and a low of $6.00. This represents a 1894.05% increase from the last price of $0.84.

- $5 $10 $15 $20 $25 High: $24 Avg: $16.75 Low: $6 Last Closed Price: $0.84

NKTR Stock Rating

Nektar Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

NKTR Forecast vs Benchmarks

TypeNameUpside
StockNektar Therapeutics1894.05%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.84$0.84$0.84
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25223-18
Dec, 24213-17
Nov, 24553-114
Oct, 245531115
Sep, 245531115
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 18, 2022Mara GoldsteinMizuho Securities$6.00$4.7426.58%614.29%
Mar 01, 2022Jessica FyeJ.P. Morgan$17.00$10.9854.83%1923.81%
Nov 08, 2021Aydin HuseynovLadenburg Thalmann & Co.$20.00$14.6536.52%2280.95%
May 18, 2021Chris ShibutaniGoldman Sachs$24.00$18.1332.38%2757.14%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024Piper SandlerOverweightinitialise
Jun 28, 2024Rodman & RenshawBuyinitialise
Nov 09, 2023Cowen & Co.Outperformupgrade
May 10, 2023JefferiesHoldupgrade
Mar 06, 2023OppenheimerPerformPerformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.49$-2.86$-1.97$-1.45-----
Avg Forecast$-2.50$-2.90$-2.13$-1.44$-0.72$-0.77$-0.70$-0.75$-0.76
High Forecast$-3.36$-3.89$-3.72$-1.47$-0.83$-0.93$-0.89$-1.05$-1.41
Low Forecast$-0.99$-1.15$-0.99$-1.41$-0.46$-0.61$-0.38$-0.29$-0.21
Surprise %-0.40%-1.38%-7.51%0.69%-----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$152.91M$101.91M$92.06M$90.12M-----
Avg Forecast$159.25M$111.04M$91.46M$84.89M$104.74M$81.59M$80.39M$89.61M$139.94M
High Forecast$85.40M$59.55M$53.80M$72.68M$90.37M$37.45M$79.08M$89.41M$62.83M
Low Forecast$201.22M$140.30M$144.24M$91.13M$155.05M$139.21M$81.71M$89.81M$233.57M
Surprise %-3.98%-8.23%0.65%6.17%-----

Net Income Forecast

$-750M $-600M $-450M $-300M $-150M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-444.44M$-523.84M$-368.20M$-276.06M-----
Avg Forecast$-493.94M$-555.71M$-614.62M$-276.06M$-121.91M$-172.26M$-121.25M$-127.20M$-143.64M
High Forecast$-592.73M$-666.85M$-737.55M$-331.27M$-156.88M$-176.13M$-169.57M$-199.75M$-268.58M
Low Forecast$-395.16M$-444.57M$-491.70M$-220.84M$-86.95M$-116.82M$-72.93M$-54.65M$-40.74M
Surprise %-10.02%-5.74%-40.09%------

NKTR Forecast FAQ

Is Nektar Therapeutics stock a buy?

Nektar Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nektar Therapeutics is a favorable investment for most analysts.

What is Nektar Therapeutics's price target?

Nektar Therapeutics's price target, set by 4 Wall Street analysts, averages $16.75 over the next 12 months. The price target range spans from $6 at the low end to $24 at the high end, suggesting a potential 1894.05% change from the previous close price of $0.84.

How does Nektar Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Nektar Therapeutics stock forecast shows a 1894.05% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Nektar Therapeutics over the past three months?

  • January 2025: 25.00% Strong Buy, 25.00% Buy, 37.50% Hold, 0% Sell, 12.50% Strong Sell.
  • December 2024: 28.57% Strong Buy, 14.29% Buy, 42.86% Hold, 0% Sell, 14.29% Strong Sell.
  • November 2024: 35.71% Strong Buy, 35.71% Buy, 21.43% Hold, 0% Sell, 7.14% Strong Sell.

What is Nektar Therapeutics’s EPS forecast?

Nektar Therapeutics's average annual EPS forecast for its fiscal year ending in December is -0.72 for 2024, a -50.34% decrease from the reported $-1.45 in 2023. The prediction for 2025 is $-0.77, $-0.7 for 2026, $-0.75 for 2027, and $-0.76 for 2028.

What is Nektar Therapeutics’s revenue forecast?

Nektar Therapeutics's average annual revenue forecast for its fiscal year ending in December is $104.74M for 2024, a 16.22% increase from the reported $90.12M in 2023. The forecast for 2025 is $81.59M, $80.39M for 2026, $89.61M for 2027, and $139.94M for 2028.

What is Nektar Therapeutics’s net income forecast?

For its fiscal year ending in December, Nektar Therapeutics's average annual net income forecast is $-122M for 2024, reflecting a -55.84% decrease from the reported $-276M in 2023. The projection for 2025 is $-172M, $-121M for 2026, $-127M for 2027, and $-144M for 2028.